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Abstract
An investigation of clinical and laboratory variables which might form the basis for judging disease activity in clinical practice was made by six rheumatologists in a prospective study of up to three years' duration of 113 patients with early rheumatoid arthritis. Decisions to start treatment with slow acting antirheumatic drugs were equated with moments of high disease activity. If treatment with slow acting antirheumatic drugs was not started or if the slow acting antirheumatic drug remained unchanged for at least one year or if treatment was stopped because of disease remission, this was equated with periods of low disease activity. Two groups, one with high and one with low disease activity according to the above criteria, were formed. Factor analysis was performed to enable easy handling of the large number of clinical and laboratory variables without loss of information; this resulted in five factors. Next, discriminant analysis was done to determine to what extent each factor contributed to discrimination between the two groups of differing disease activity. Finally, a multiple regression analysis was carried out to determine which laboratory and clinical variables underlie the factors of the discriminant function, resulting in a 'disease activity score'. This score consisted of the foliowing variables: Ritchie index, swoilen joints, erythrocyte sedimentation rate, and general health, in declining importance. The rheumatologists' decisions to prescribe slow acting antirheumatic drugs, or not, were mainly based on articular symptoms.
In rheumatoid arthritis disease activity cannot be measured by one single variable. In clinical practice an opinion of disease activity is formed from a combination of information, such as laboratory and clinical variables, radiological assessments, and overall impression of the patient. This clinical judgment ofdisease activity varies considerably among different rheumatologists as has been shown by Kirwan To find some structure in the large number of variables, factor analysis was performed, resulting in a few factors to be used in the further analysis. The patients' records were then divided (according to explicit rules) into a group with high and one with low disease activity. This selection was the basis of a discriminant analysis to determine how the factors might best be combined to produce a score which reflects the disease activity most accurately: the disease activity score. The reproducibility of the factors was studied with a correlation matrix analysis between periods. Subsequently, a multiple regression analysis was performed to determine how the disease activity score might best be measured in practice.
Results Table 1 shows some general characteristics of the patients. Table 2 summarises the variables used in the analysis. Because of a high skewness some variables were transformed to approximate a normal distribution. These transformed values were used in the analysis. As the variable 'total protein' depends fully on the other components of the protein analysis, and the variable 'fatigue' showed no change over the time, these two variables were excluded from the analysis.
FACTOR ANALYSIS
Initially, a factor analysis on the complete data was performed. Three factors with Eigen values higher than 1 and a cumulative percentage of explained variance of 59% were analysed further. Table  4 summarises the five factors with the variables with the highest loadings on these factors. In conclusion, factor analysis of individual data gives the most easily interpreted results and the greatest explained variance. The factors can be labelled as variables of inflammation in the blood (factor 1), variables of joint examination (factor 2), protein analysis (factor 3), subjective complaints (factor 4), and grip strength (factor 5). Two factors (1 and 3) are objective measurements, factor 2 is a semiobjective assessment, factor 4 reflects the subjective complaints of the patient, and factor 5 combines disease activity and structural (irreversible) damage of the hand.
CALCULATION OF THE FACTOR VALUES
The standard deviation score (Z score= (observed value-mean)/standard deviation) was calculated for all variables at each visit. The measurement quality of the factors is very important in longitudinal studies. Fortunately, owing to the repetition of measurements, it was possible to estimate this quality in the study using the interperiod correlation matrix. Thus the intercorrelation of five periods (months) was plotted against the intervening time intervals (one to four months). When the short time interval was taken into account the correlations were linearly related to time, which may be represented by a well fitting regression line (correlation v time interval). Extrapolation of this line to a time interval of zero gave the direct measurement-remeasurement correlation, which may be interpreted as a quality measure of the factor. Table 5 presents the results of the estimations.
DEFINITION OF DISEASE ACTIVITY
The overall judgment of the rheumatologist was the starting point in assessing disease activity. Indeed, the decision to start or terminate slow acting antirheumatic drugs was used as the criterion. The decision to start slow acting antirheumatic drugs was taken by the rheumatologists independently of the clinical assessments of the research nurses.
The defmnition of high disease activity was (a) start of a slow acting antirheumatic drug; (b) termination of treatment with slow acting antirheumatic drugs because of lack of effect. The defmition of low disease activity was (a) termination of treatment with slow acting antirheumatic drugs because of remission of the rheumatoid arthritis; (b) not changing a slow acting antirheumatic drug for at least one year; (c) not starting treatment with a slow acting antirheumatic drug for at least one year. If a patient met the above criteria more than once only the observations made at an interval of at least five months were included. Ultimately, 78 patients met these conditions, with the numbers Table 7 Computation ofthe disease activity scores. The units used in the formulas are given in table 2 Disease activity score (four variables)= D4=0-53938xsq rt (Ritchie score)+0 06465x(number of swollen joints)+ 0330xIn(ESR)+0 00722x(general health)
Disease activity score (three variables)= D3=0-53938xsq rt (Ritchie score)+0 06465x(number of swollen joints)+ 0-330xln(ESR)+0-224 situation, a survey of judging disease activity on such patients does not necessarily reflect the process of actual decision making in practice. 1 6 This study describes judging disease activity in actual practice. We opted for a real decision point in patient management: the moment when the rheumatologist considered the rheumatoid arthritis so active that the patient had to start treatment with or change slow acting drugs was marked as high disease activity. Conversely, patients who were not treated with slow acting antirheumatic drugs or continued to take the same slow acting antirheumatic drug during at least one year were placed in the group of low disease activity. In addition to disease activity other factors may lead to the start or withdrawal of a slow acting antirheumatic drug-for example, the refusal of the patient. These factors might have interfered with the appropriate classification of patients. This probably played a part in only a few patients, so we did not correct for possible misclassification as this might have introduced a subjective interpretation.
We were able to describe the real process of decision making in practice because the rheumatologists were unaware that their decisions were part of an investigation. Moreover, smaller numbers of patients are needed since no correction has to be made for multiple statistical testing. In practice the validated disease activity score might be used to assess the disease activity of an individual patient and determine objectively when to start using a slow acting antirheumatic drug. In addition, the efficacy of the slow acting antirheumatic drug may be determined: an improvement of the score by 1-08 (=2x standard error) or more is a statistically significant improvement. This provides clear information, helpful in the management of individual patients.
The value of the disease activity score is currently under investigation and will become apparent in the future. 
